145 related articles for article (PubMed ID: 38644547)
1. CAR-T cell therapy: unravelling its potential in extra-nodal diffuse large B cell lymphoma.
Khan SJ; Alhaj Moustafa M
Chin Clin Oncol; 2024 Apr; 13(2):31. PubMed ID: 38644547
[No Abstract] [Full Text] [Related]
2. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
[TBL] [Abstract][Full Text] [Related]
5. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
6. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.
Li J; Mu J; Wang J; Li X; Li Q; Jiang Y; Cui R; Deng Q
Cell Transplant; 2024; 33():9636897241247951. PubMed ID: 38651796
[TBL] [Abstract][Full Text] [Related]
7. Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
Beyar Katz O; Perry C; Grisariu-Greenzaid S; Yehudai-Ofir D; Luttwak E; Avni B; Zuckerman T; Sdayoor I; Stepensky P; Ringelstein-Harlev S; Bar-On Y; Libster D; Sharvit L; Amit O; Greenbaum U; Gold R; Herishanu Y; Benyamini N; Avivi I; Ram R
Eur J Haematol; 2023 Jul; 111(1):63-71. PubMed ID: 36964939
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
9. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
11. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
[TBL] [Abstract][Full Text] [Related]
12. Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma.
Jalbert JJ; Wu N; Chen CI; Ambati S; Ge W; Arnason JE
Adv Ther; 2022 Jun; 39(6):2630-2640. PubMed ID: 35397110
[TBL] [Abstract][Full Text] [Related]
13. CD19-directed CAR T-cell therapy in B-cell NHL.
Kersten MJ; Spanjaart AM; Thieblemont C
Curr Opin Oncol; 2020 Sep; 32(5):408-417. PubMed ID: 32740094
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.
Havard R; Stephens DM
Curr Hematol Malig Rep; 2018 Dec; 13(6):534-542. PubMed ID: 30362020
[TBL] [Abstract][Full Text] [Related]
15. T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Wang J; Shen K; Mu W; Li W; Zhang M; Zhang W; Li Z; Ge T; Zhu Z; Zhang S; Chen C; Xing S; Zhu L; Chen L; Wang N; Huang L; Li D; Xiao M; Zhou J
Front Immunol; 2022; 13():873789. PubMed ID: 35572515
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
[TBL] [Abstract][Full Text] [Related]
17. How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
Nagler A; Perriello VM; Falini L; Falini B
Br J Haematol; 2023 May; 201(3):396-410. PubMed ID: 36916189
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient.
Hu L; Wu F; Wang H; Zhu W; Wang J; Yu F; Zhai Z
Front Immunol; 2021; 12():665230. PubMed ID: 33953727
[TBL] [Abstract][Full Text] [Related]
19. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
[TBL] [Abstract][Full Text] [Related]
20. Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
Yamauchi N; Maruyama D
Eur J Haematol; 2024 May; 112(5):662-677. PubMed ID: 38168033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
